eego Harbor, Michigan-based ZIVO Bioscience, Inc. (ZIVO,) a company developing and commercializing nutritional compounds and bioactive molecules derived from its proprietary algal strains, has entered into a tolling agreement and technical services contract with Synthetic Genomics, Inc. (SGI,) based in La Jolla, California.
ZIVO has engaged SGI to produce biomass in quantity to satisfy the sample production requirements for validation in a variety of compliance studies and tests, ranging from basic toxin screening through more sophisticated digestibility and protein quality tests, as well as safety testing to meet GRAS (Generally Recognized As Safe) requirements for food and feed applications.
The algal biomass production is conducted under rigorous controls to provide a framework for anticipated cGMP (current Good Manufacturing Practice) certification as required by state and federal food safety regulations.
The initial biomass cultivation is being carried out in small bioreactors and indoor ponds, and is then expected to move to larger, outdoor ponds within the next two weeks. Special inflatable greenhouse canopies over the outdoor cultivation ponds will help protect the algae from temperature extremes and windblown debris.
These tests and studies have grown in number and scope since late April 2016 as the company has scaled up production to establish and test the parameters of commercialization. Additional sites are also being evaluated for more cultivation capacity.